GSK and Intercell form strategic alliance to develop and commercialise innovative vaccines
- Details
- Category: GlaxoSmithKline
GlaxoSmithKline Biologicals SA (GSK) and Intercell announced an agreement to form a strategic alliance to accelerate the development and commercialisation of needle-free, patch-based vaccines. The agreement will include Intercell's candidate vaccine for travellers' diarrhoea (TD) and an investigational single application pandemic influenza vaccine, as well as the use of the patch technology for other vaccines in GSK's portfolio.
Pfizer Extends Commitment to Help Unemployed Americans
- Details
- Category: Pfizer
Pfizer will extend its MAINTAIN™ (Medicines Assistance for Those who Are in Need) patient assistance program for an additional year, through December 31, 2010. In addition to the more than 70 Pfizer primary care medicines currently available through MAINTAIN, Pfizer will extend the benefits of MAINTAIN to many legacy Wyeth medicines.
Physicians More Likely To Report Drug Safety Information Through Electronic Health Records System
- Details
- Category: Pfizer
Pfizer announced today results of a survey the company recently sponsored that shows physicians are more likely to report side effects through an electronic health records (EHR) system, as compared to traditional paper methods.
Novartis Tasigna® trial shows superior results to Glivec®
- Details
- Category: Novartis
In a large Phase III clinical trial, Tasigna® (nilotinib) demonstrated greater efficacy over Glivec® (imatinib)* in the treatment of adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase[1].
Facet Biotech and Bristol-Myers Squibb Report Promising Phase I/II Interim Data for Elotuzumab
- Details
- Category: Bristol-Myers Squibb
Facet Biotech Corporation (Nasdaq: FACT) and Bristol-Myers Squibb Company (NYSE: BMY) announced that potentially promising data from a Phase I/II study of elotuzumab, an investigational humanized antibody being studied for the treatment of relapsed multiple myeloma (MM), were presented at the American Society of Hematology (ASH) 2009 Annual Meeting in New Orleans.
Novo Nordisk starts phase 1 trial with oral insulin analogue
- Details
- Category: Novo Nordisk
Novo Nordisk has initiated its first phase 1 clinical trial with an oral insulin analogue (NN1952). This milestone releases a USD 2 million payment to Merrion Pharmaceuticals plc, whose GIPET® technology is used in the formulation of NN1952.
Sanofi-aventis enters into an Exclusive Global Licensing Agreement with The Rockefeller University
- Details
- Category: Sanofi
Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced an exclusive global licensing agreement with The Rockefeller University (New York, NY) concerning a novel monoclonal antibody, targeting certain specific forms of the Amyloid Beta parenchymal plaque for the treatment of Alzheimer's disease.
More Pharma News ...
- New Amgen Scholars Web site Launches to Build a Global Network for Future Scientists
- AstraZeneca and Targacept Form Global Collaboration and Licence Agreement
- Resource Guide About Key Issues Facing the Pharmaceutical Industry
- GSK's Arepanrix⢠H1N1 pandemic vaccine prequalified by the World Health Organization
- Merck KGaA Receives Refuse to File Letter from FDA on Cladribine Tablets New Drug Application
- Pfizer And Protalix Enter Into Agreement To Develop And Commercialize Gaucher's Disease Treatment
- "Positive Charge" to Help Address Barriers and Provide Support to People Living with HIV/AIDS